The SARS-CoV-2-neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine

Kidney Int. 2021 Nov;100(5):1129-1131. doi: 10.1016/j.kint.2021.09.006. Epub 2021 Sep 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19 Vaccines*
  • COVID-19* / immunology
  • Humans
  • Kidney Transplantation*
  • SARS-CoV-2
  • Transplant Recipients*

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • BNT162 Vaccine